The PNH sub-clinical type is a questionable disease in the field of blood tumours, with clinical performance being complex and often involving multi-system congestion. Early identification and normalisation of the diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of PNH sub-clinical treatment programs require individualized development, typically including multidimensional management, including drug therapy, rehabilitation interventions, and regular follow-up visits. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult to treat blood tumour diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the PNH clinical type. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.